BioCurex, Inc.(fka BOCX)

[was Gyro]

This article is mostly about M&A activity, not bocx per se, but I thought the last few paragraphs were interesting in the context of Biocurex and some of the takeover conversations that we've had here. (This article mentions both ABT and IMA, so I was hoping for a connection somehow - there's not.)

---
"...Developing a new medical device is generally far less expensive than taking a new drug through trials, getting it approved by regulators and bringing it to market, according to Edison's Davison.

But while a biotechnology company that's gotten that far can generally expect a pipeline-hungry big pharma partner to step in with a licensing deal, medtechs might have to prove that their product will actually sell.

Davison said physicians are often reluctant to use new technology, meaning that it's hard for small companies to move new products in the market. They must either build up their own sales force, look for a distribution deal or put themselves up for sale in the hope of getting access to a greater number of surgeons and hospitals.

"Once you get to that stage there's a definite rationale for being bought," added Nomura Code's Weston. "A really good product is worth far more in the hands of a big company."
"
---

Full article at http://money.cnn.com/news/newsfeeds/articles/djf500/200802110758DOWJONESDJONLINE000211_FORTUNE5.htm